LTRN – Lantern Pharma Inc
Lantern Pharma Inc.LTRN
$4.33Name : Lantern Pharma Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $46,697,752.00
EPSttm : -1.78
Lantern Pharma Inc.
$4.33
0.00%$0.0000Float Short %
2.97
Margin Of Safety %
Put/Call OI Ratio
0.08
EPS Next Q Diff
0.42
EPS Last/This Y
EPS This/Next Y
0.32
Price
4.38
Target Price
20.5
Analyst Recom
1
Performance Q
37.03
Relative Volume
0.65
Beta
1.6
Ticker: LTRN
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-01-23 | LTRN | 4.16 | 0.10 | 0.00 | 179 |
| 2025-01-24 | LTRN | 5.45 | 0.10 | 0.02 | 182 |
| 2025-01-27 | LTRN | 4.68 | 0.08 | 0.40 | 736 |
| 2025-01-28 | LTRN | 4.69 | 0.09 | 0.25 | 696 |
| 2025-01-29 | LTRN | 4.56 | 0.09 | 0.00 | 696 |
| 2025-01-30 | LTRN | 4.97 | 0.08 | 0.40 | 795 |
| 2025-01-31 | LTRN | 4.98 | 0.09 | 0.00 | 828 |
| 2025-02-03 | LTRN | 4.68 | 0.09 | 0.00 | 828 |
| 2025-02-04 | LTRN | 4.71 | 0.09 | 0.00 | 808 |
| 2025-02-05 | LTRN | 5.08 | 0.09 | 0.02 | 809 |
| 2025-02-06 | LTRN | 5.25 | 0.09 | 0.31 | 852 |
| 2025-02-07 | LTRN | 5.07 | 0.10 | 0.07 | 883 |
| 2025-02-10 | LTRN | 5.02 | 0.10 | 0.07 | 883 |
| 2025-02-11 | LTRN | 4.89 | 0.11 | 0.00 | 875 |
| 2025-02-12 | LTRN | 4.96 | 0.10 | 0.40 | 892 |
| 2025-02-13 | LTRN | 4.74 | 0.10 | 0.00 | 892 |
| 2025-02-14 | LTRN | 5.01 | 0.10 | 0.00 | 967 |
| 2025-02-18 | LTRN | 4.56 | 0.09 | 0.04 | 990 |
| 2025-02-19 | LTRN | 4.63 | 0.09 | 0.00 | 998 |
| 2025-02-20 | LTRN | 4.3 | 0.09 | 0.03 | 1069 |
| 2025-02-21 | LTRN | 4.3 | 0.08 | 1.20 | 1097 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-01-23 | LTRN | 4.17 | - | - | -1.93 |
| 2025-01-24 | LTRN | 5.40 | - | - | -1.93 |
| 2025-01-27 | LTRN | 4.60 | - | - | -1.93 |
| 2025-01-28 | LTRN | 4.58 | - | - | -1.93 |
| 2025-01-29 | LTRN | 4.57 | - | - | -1.93 |
| 2025-01-30 | LTRN | 4.81 | - | - | -1.93 |
| 2025-01-31 | LTRN | 4.95 | - | - | -1.93 |
| 2025-02-03 | LTRN | 4.67 | - | - | -1.93 |
| 2025-02-04 | LTRN | 4.80 | - | - | -1.93 |
| 2025-02-05 | LTRN | 5.14 | - | - | -1.93 |
| 2025-02-06 | LTRN | 5.25 | - | - | -1.93 |
| 2025-02-07 | LTRN | 5.03 | - | - | -1.93 |
| 2025-02-10 | LTRN | 5.05 | - | - | -1.93 |
| 2025-02-11 | LTRN | 4.82 | - | - | -1.93 |
| 2025-02-12 | LTRN | 4.89 | - | - | -1.93 |
| 2025-02-13 | LTRN | 4.83 | - | - | -1.93 |
| 2025-02-14 | LTRN | 5.01 | - | - | -1.93 |
| 2025-02-18 | LTRN | 4.58 | - | - | -1.93 |
| 2025-02-19 | LTRN | 4.64 | - | - | -1.93 |
| 2025-02-20 | LTRN | 4.36 | - | - | -1.93 |
| 2025-02-21 | LTRN | 4.38 | - | - | -1.93 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-01-23 | LTRN | 0.00 | 3.70 | 2.42 |
| 2025-01-24 | LTRN | 0.00 | 3.70 | 2.42 |
| 2025-01-27 | LTRN | 0.00 | 2.20 | 2.42 |
| 2025-01-28 | LTRN | 0.00 | 2.20 | 2.33 |
| 2025-01-29 | LTRN | 0.00 | 2.20 | 2.33 |
| 2025-01-30 | LTRN | 0.00 | 2.20 | 2.33 |
| 2025-01-31 | LTRN | 0.00 | 2.20 | 2.33 |
| 2025-02-03 | LTRN | 0.00 | -2.37 | 2.33 |
| 2025-02-04 | LTRN | 0.00 | -2.37 | 2.33 |
| 2025-02-05 | LTRN | 0.00 | -2.37 | 2.33 |
| 2025-02-06 | LTRN | 0.00 | -2.37 | 2.33 |
| 2025-02-07 | LTRN | 0.00 | -2.37 | 2.33 |
| 2025-02-10 | LTRN | 0.00 | -1.78 | 2.33 |
| 2025-02-11 | LTRN | 0.00 | -1.78 | 2.33 |
| 2025-02-12 | LTRN | 0.00 | -1.78 | 2.97 |
| 2025-02-13 | LTRN | 0.00 | -1.78 | 2.97 |
| 2025-02-14 | LTRN | 0.00 | -1.78 | 2.97 |
| 2025-02-18 | LTRN | 0.00 | 74.26 | 2.97 |
| 2025-02-19 | LTRN | 0.00 | 74.26 | 2.97 |
| 2025-02-20 | LTRN | 0.00 | 74.26 | 2.97 |
| 2025-02-21 | LTRN | 0.00 | 74.26 | 2.97 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.42
Avg. EPS Est. Current Quarter
Avg. EPS Est. Next Quarter
Insider Transactions
Institutional Transactions
74.26
Beta
1.6
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
7
Growth Score
20
Sentiment Score
50
Actual DrawDown %
82.4
Max Drawdown 5-Year %
Target Price
20.5
P/E
Forward P/E
PEG
P/S
P/B
1.76
P/Free Cash Flow
EPS
-1.77
Average EPS Est. Cur. Y
-1.93
EPS Next Y. (Est.)
-1.61
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
0.65
Return on Equity vs Sector %
-91
Return on Equity vs Industry %
-75.4
EPS 1 7Days Diff
0.1
EPS 1 30Days Diff
0.13
EBIT Estimation
Lantern Pharma Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 21
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and pediatric rare disease designation. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Further, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. Lantern Pharma Inc. has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications. The company was incorporated in 2013 and is headquartered in Dallas, Texas.
stock quote shares LTRN – Lantern Pharma Inc Stock Price stock today
news today LTRN – Lantern Pharma Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch LTRN – Lantern Pharma Inc yahoo finance google finance
stock history LTRN – Lantern Pharma Inc invest stock market
stock prices LTRN premarket after hours
ticker LTRN fair value insiders trading